MedPath

Eye Therapies, LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:3

Trial Phases

2 Phases

Phase 1:1
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (66.7%)
Phase 1
1 (33.3%)

Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension

Phase 1
Completed
Conditions
Glaucoma and Ocular Hypertension
Interventions
First Posted Date
2012-09-19
Last Posted Date
2012-12-25
Lead Sponsor
Eye Therapies, LLC
Target Recruit Count
15
Registration Number
NCT01687426
Locations
🇺🇸

Clinical Site, Winchester, Massachusetts, United States

Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects

Phase 2
Completed
Conditions
Ocular Redness
Interventions
First Posted Date
2012-08-30
Last Posted Date
2014-07-31
Lead Sponsor
Eye Therapies, LLC
Target Recruit Count
57
Registration Number
NCT01675609
Locations
🇺🇸

Ora, Inc., Andover, Massachusetts, United States

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

Phase 2
Completed
Conditions
Allergic Conjunctivitis
Interventions
First Posted Date
2011-01-12
Last Posted Date
2012-03-06
Lead Sponsor
Eye Therapies, LLC
Target Recruit Count
68
Registration Number
NCT01275105
Locations
🇺🇸

Ora, Inc., Andover, Massachusetts, United States

News

Federal Circuit Reverses Patent Board Ruling on Eye Redness Treatment, Strengthens Brimonidine Patent Protection

The Federal Circuit reversed the Patent Trial and Appeal Board's obviousness ruling that invalidated Eye Therapies' patent claims for brimonidine-based eye redness treatments.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.